MYUNGIN PHARM.CO., LTD

317450· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩42,450-0.35%

2026-09-18

Financials

Valuation Metrics

MYUNGIN PHARM.CO., LTD's Market Cap is ₩6198B. Ranked #410 of 2,421 in KR market (top 17%), #270 of 781 on KOSPI (top 35%), #46 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	619.77B KRW	KR#410/2,421 Sec#46/231
Revenue	287.25B KRW	KR#848/2,421 Sec#39/231
Net Income	81.44B KRW	KR#290/2,421 Sec#19/231
Total Assets	841.67B KRW	KR#533/2,421 Sec#29/231
Net Assets	794.38B KRW	KR#349/2,421 Sec#22/231
Value
P/E	7.61x	KR#628/2,421 Sec#28/231
P/B	0.78x	KR#1,233/2,421 Sec#73/231
P/S	2.16x	KR#1,856/2,421 Sec#105/231
EV/EBITDA	6.36x	KR#331/2,421 Sec#10/231
FCF Yield	8.31%	KR#677/2,421 Sec#33/231
Profitability
ROE	10.25%	KR#591/2,421 Sec#41/231
ROA	9.68%	KR#291/2,421 Sec#23/231
Op. Margin	32.20%	KR#48/2,421 Sec#11/231
Financial Health
Debt Ratio	5.95%	KR#48/2,421 Sec#14/231
Total Debt	0 KRW	KR—/2,421 Sec—/231
FCF	51.52B KRW	KR#286/2,421 Sec#16/231
Cash	31.79B KRW	KR#976/2,421 Sec#66/231
Current Ratio	13.93x	KR#57/2,421 Sec#17/231
Net Debt/EBITDA	-0.34x	KR#537/2,421 Sec#31/231
Dividend
Div. Yield	3.53%	KR#518/2,421 Sec#21/231
Performance
1M Return	-7.31%	KR#1,955/2,421 Sec#159/231
From 52W High	-68.44%	KR#2,154/2,421 Sec#183/231
1Y MDD	-67.35%	KR#1,851/2,421 Sec#152/231
Trading
Volume	4,830 shares	KR#2,128/2,421 Sec#203/231
Trading Value	205.3M KRW	KR#1,265/2,421 Sec#128/231
Foreign Own.	0.89%	KR#2,074/2,421 Sec#203/231
Per Share
EPS	5,578 KRW	KR#196/2,421 Sec#10/231
BPS	54,409 KRW	KR#246/2,421 Sec#14/231

Company Info

CEO 이행명

Founded 1988

HQ 경기도 화성시, KR

Website www.myunginph.co.kr

동사는 1985년 설립되어 유가증권시장에 상장한 중추신경계 치료 약물 전문기업임. 치매, 파킨슨, 뇌전증 등 신경계 약물과 조현병, 우울증, 불안 및 수면치료제 시장에서 국내 1위를 차지하고 있음. 일반의약품 이가탄F와 메이킨Q는 높은 인지도로 시장 선점 중이며, 원료합성부터 완제 의약품 생산까지 전 공정 기술력과 cGMP 기준 생산설비를 보유, 글로벌 제약사와 협력하고 있음. 명인제약는 1988년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.